Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI

Pharmazie

Volumn 68, Issue 7, 2013, Pages 549-554

  Muhlstein A ^a   Gelperina, S ^b   Kreuter, J ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Nanosystem LTD   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

GALSULFASE; NANOPARTICLE;

ARTICLE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG DETERMINATION; ENZYME REPLACEMENT; MAROTEAUX LAMY SYNDROME; PH;

ADSORPTION; ALGORITHMS; BLOOD-BRAIN BARRIER; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, GEL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ENZYME REPLACEMENT THERAPY; EXCIPIENTS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; NANOPARTICLES; PARTICLE SIZE; THERMODYNAMICS;

EID: 84882990208     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.6502     Document Type: Article

References (27)

1. Agogbua SI,Wynn CH (1976) Purification and properties of arylsulphatase B of human liver. Biochem J 153: 415-421.
2. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyano acrylate nanoparticles. Pharm Res 14: 325-328.
3. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J (1998) Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: An in situ brain perfusion study. J Microencapsul 15: 67-74.
4. Auclair D, Finnie J, White J, Nielsen T, Fuller M, Kakkis E, Cheng A, O'Neill CA, Hopwood JJ (2010) Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Mol Genet Metab 99: 132-141.
5. Auclair D, Finnie J, Walkley SU, White J, Nielsen T, Fuller M, Cheng A, O'Neill CA, Hopwood JJ (2012) Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr Res 71: 39-45.
6. Baum H, Dodgson KS, Spencer B (1959) The assay of arylsulphatases A and B in human urine. Clin Chim Acta 4: 453-455.
7. Blanco MD, Alonso MJ (1997) Development and characterization of protein-loaded poly (lactide-co-glycolide) nanospheres. Eur J Pharm Biopharm 43: 287-294.
8. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P (1979) Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: Preparation, morphological and sorptive properties. J Pharm Pharmacol 31: 331-332.
9. Fuller M, Brooks DA, Evangelista M, Hein LK, Hopwood JJ, Meikle PJ (2005) Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 84: 18-24.
10. Gibson GJ, Saccone GT, Brooks DA, Clements PR, Hopwood JJ (1987) Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr values. Biochem J 248: 755-764.
11. Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P, Mobley W, Dickson P, Hanson S, Passage M (2004) Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 83: 163-174.
12. Kreuter J (1983) Physicochemical characterization of polyacrylic nanoparticles. Int J Pharm 14: 43-58.
13. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674: 171-174.
14. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R (2002) Apolipoprotein-mediated transport of nanoparticlebound drugs across the blood-brain barrier. J Drug Target 10: 317-325.
15. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS, Kreuter J, Gelperina S, Begley D, Alyautdin RN (2009) Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 17: 564-574.
16. Langer K, Seegmüller E, Zimmer A, Kreuter J (1994) Characterisation of polybutylcyanoarylate nanoparticles: I. Quantification of PCBA polymer and dextrans. Int J Pharm 110: 21-27.
17. Langmuir I (1916) The constitution and fundamental properties of solids and liquids. Part I. Solids. J Am Chem Soc 38: 2221-2295.
18. Lukatela G, Krauss N, Theis K, Selmer T, Gieselmann V, von Figura K, Saenger W (1998) Crystal structure of human arylsulfatase A: The aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. Biochemistry 37: 3654-3664.
19. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K (2006) Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 317: 1246-1253.
20. Nonckreman CJ, Fleith S, Rouxhet PG, Dupont-Gillain CC (2010) Competitive adsorption of fibrinogen and albumin and blood platelet adhesion on surfaces modified with nanoparticles and/or PEO. Colloids Surf B Biointerfaces 77: 139-149.
21. Richardson NE, Meakin BJ (1974) The sorption of benzocaine from aqueous solution by nylon 6 powder. J Pharm Pharmacol 26: 166-174.
22. Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, Micieli D, Pignatello R, Capulli M, Rucci N, Angelucci A, Del Fattore A, Teti A, Zini N, Giunti A, Baldini N (2010) Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets 10: 649-659.
23. Steiniger SCJ, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109: 759-767.
24. Wang Y, Hanson M (1988) Formulations of proteins and peptides: Stability and stabilizers. J. Parenter. Sci. Technol. 42: 3-26.
25. Wraith JE (2006) Limitations of enzyme replacement therapy: Current and future. J Inherit Metab Dis 29: 442-447.
26. Yaghootfam A, Schestag F, Dierks T, Gieselmann V (2003) Recognition of arylsulfatase A and B by the UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-phosphotransferase. J Biol Chem 278: 32653-32661.
27. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Buchel C, von Briesen H, Kreuter J (2009) Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 137: 78-86.